In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cipla Limited

Can The Pipeline Soothe A US Generics Pricing Headache?

Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.

Generic Drugs Sales & Earnings

Cipla Lines Up Advair But Costs Will Flatten High-Value Launches

A generic version of Advair is high on Cipla’s plans for its current financial year ending in March 2023. Management discussed the high-value respiratory asset and the company’s further prospects during the Indian firm’s annual earnings call, which included the company passing $1bn in sales for its domestic branded prescription business.

Sales & Earnings Strategy

Can The Pipeline Soothe A US Generics Pricing Headache?

Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.

Generic Drugs Sales & Earnings

Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India

Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?

India Commercial
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Medical Devices
  • Pharmaceuticals
  • Services
    • Consulting Services
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Cipla Gulf FZ LLC
    • Cipla Technologies LLC
    • InvaGen Pharmaceuticals Inc.
    • Mirren Pty, Ltd.
UsernamePublicRestriction

Register